
Mural Oncology, Inc.: Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: FinanzNachrichten.de
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety